Galaxy Biomedical Investment Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2019

Galaxy Biomedical Investment Co., Ltd., formerly Beihai Yinhe Industry Investment Co., Ltd., is a China-based company principally engaged in biomedical business. The Company mainly operates through three business segments. Biomedical segment is mainly engaged in the research and development of innovative drugs, model animal construction, tumor immune cell therapy and the development of stem cell technology. Electricity Transmission and Distribution segment is mainly engaged in the manufacture and sale of transformer products in various specifications and types. Electronic segment mainly provides various types of displacement sensors, brake resistance boxes, radio frequency (RF) components, resistors and potentiometers, among others. The Company distributes its products mainly in domestic market, with eastern China as its main market.